secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001193125-22-302295
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera submits NDA for avasopasem to reduce severe oral mucositis in head & neck cancer
--------------------------------------------------------------------------------

- NDA for avasopasem submitted to FDA for radiotherapy-induced severe oral mucositis (SOM) in head/neck cancer.
- Two positive placebo-controlled trials (Phase 3 ROMAN, Phase 2b GT-201) enrolled 678 patients total.
- ROMAN trial: statistically significant reduction in SOM incidence; median SOM days more than halved vs placebo.
- Prospectively defined analysis showed avasopasem reduced cisplatin-related chronic kidney disease by 50%.
- FDA previously granted Fast Track and Breakthrough Therapy designations; no approved SOM drug currently exists.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312522302295/0001193125-22-302295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312522302295/d371259d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-302295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer